LEMAITRE VASCULAR INC (LMAT)
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Instruments & Supplies
LeMaitre Vascular, Inc.
Trials need funding. See this company's dilution risk and cash position.
- Phase 2Terminated
Study to Evaluate the Performance and Safety of Expedial and Compare it to Expanded Polytetrafluoroethylene (ePTFE) Vascular Access Grafts
Expedial Vascular Access Graft
End Stage Renal Disease
NCT00131872Enrollment172StartMar 2004Primary Completion-CompletionNov 2006 - Not applicableActive, not recruiting
Evaluate Safety and Effectiveness of XenoSure® Biological Patch in the Application of Peripheral Vascular Repair
Implant the XenoSure patch, Repair/reconstruction of the diseased vessel
Vascular Diseases
NCT03173703Enrollment144StartJul 2017Primary CompletionNov 2025est.CompletionNov 2025est. - Not applicableCompleted
Evaluate Safety and Effectiveness of XenoSure Biological Patch in the Application of Cardiac Repair
Open heart surgery to address the heart disease, Close the defects with XenoSure Patch
Heart Diseases
NCT03176225Enrollment142StartAug 2017Primary CompletionNov 2020CompletionFeb 2024 - ObservationalActive, not recruiting
Prospective and Non-randomized Registry of CardioCel 3D
CardioCel implantation
Intracardiac and Septal Defects, Valve and Anulus Repair +3
NCT04175327Enrollment200StartAug 2020Primary CompletionNov 2025est.CompletionMar 2026est. - ObservationalCompleted
LeMaitre LifeSpan® ePTFE Vascular Graft Retrospective Registry
AV Access, PVP
Diseased or Occluded Blood Vessels, Arteriovenous Shunting for Blood Access
NCT04620889Enrollment153StartNov 2020Primary CompletionNov 2023CompletionNov 2023 - ObservationalActive, not recruiting
Post-Market Registry in Europe and US for the Use of VascuCelTM
great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing
Great Vessel Reconstruction, Peripheral Vessel Reconstruction +1
NCT04906824Enrollment100StartJun 2023Primary CompletionOct 2025est.CompletionSep 2026est. - Not applicableRecruiting
A PMCF Study to Confirm the Performance and Safety of the LeMaitre® TufTex Single Lumen Embolectomy Catheter
TufTex Single Lumen Embolectomy Catheter
Arterial Thromboembolism
NCT05386277Enrollment112StartJan 2022Primary CompletionJun 2027est.CompletionJun 2027est. - Not applicableRecruiting
A PMCF Study Confirm the Performance and Safety of the TufTex Over-the-Wire (OTW) Embolectomy Catheters
TufTex Over-the-Wire Embolectomy Catheter
Thrombus, Embolus +1
NCT05386342Enrollment112StartJan 2023Primary CompletionJun 2027est.CompletionJun 2027est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 2 | Terminated | Expedial Vascular Access Graft | NCT00131872 |
| Not applicable | Active, not recruiting | Implant the XenoSure patch, Repair/reconstruction of the diseased vessel | NCT03173703 |
| Not applicable | Completed | Open heart surgery to address the heart disease, Close the defects with XenoSure Patch | NCT03176225 |
| Observational | Active, not recruiting | CardioCel implantation | NCT04175327 |
| Observational | Completed | AV Access, PVP | NCT04620889 |
| Observational | Active, not recruiting | great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing | NCT04906824 |
| Not applicable | Recruiting | TufTex Single Lumen Embolectomy Catheter | NCT05386277 |
| Not applicable | Recruiting | TufTex Over-the-Wire Embolectomy Catheter | NCT05386342 |